drugset / Trial / NCT00631150

A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy

NCT00631150

Phase 4 Completed 35 enrolled UCB Pharma
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Patients in community-based practices correspond to the 25% of patients who need a first add-on drug when not controlled by their standard monotherapy drug. This was a therapeutic use trial in which the population corresponds more closely to that seen in daily clinical practice.

Timeline

Start
2003-03
Primary completion
2004-07
Completion
2004-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified

Indications